Jasper Therapeutics, Inc.
JSPR
$0.73
$0.034.14%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.07M | 5.14M | 4.49M | 4.26M | 5.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.21M | 10.95M | 15.35M | 17.36M | 27.08M |
| Operating Income | -9.21M | -10.95M | -15.35M | -17.36M | -27.08M |
| Income Before Tax | -2.76M | -1.17M | -9.10M | -18.74M | -26.72M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.76M | -1.17M | -9.10M | -18.74M | -26.72M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.76M | -1.17M | -9.10M | -18.74M | -26.72M |
| EBIT | -9.21M | -10.95M | -15.35M | -17.36M | -27.08M |
| EBITDA | -9.19M | -10.93M | -15.06M | -17.13M | -26.82M |
| EPS Basic | -0.10 | -0.04 | -0.32 | -1.13 | -1.74 |
| Normalized Basic EPS | -0.06 | -0.03 | -0.19 | -0.64 | -1.09 |
| EPS Diluted | -0.10 | -0.04 | -0.32 | -1.13 | -1.74 |
| Normalized Diluted EPS | -0.06 | -0.03 | -0.19 | -0.64 | -1.09 |
| Average Basic Shares Outstanding | 28.70M | 28.67M | 28.66M | 16.64M | 15.33M |
| Average Diluted Shares Outstanding | 28.70M | 28.67M | 28.66M | 16.64M | 15.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |